juno logo.png

These new therapies continue to amaze...

Article here

"CAR-T developer Juno Therapeutics has reported data suggesting the benefits of this type of cancer immunotherapy could extend long after the treatment is delivered."

"...the case study 'shows the ability of anti-CD19 CAR-T cells to re-expand in vivo months after the initial CAR T-cell infusion and to re-exert antitumor activity' "

"The big question now is why the CAR-T cells re-activated. The researchers suggest that it may have been a result of the biopsy procedure itself, triggering the response when the presence of the tumour on its own was not sufficient."